The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: Citi Raises BHP Billiton And Rio Tinto To Buy

Fri, 10th Jul 2015 08:37

LONDON (Alliance News) - The following shares received analyst recommendations Friday morning:
----------
FTSE 100
----------
CITIGROUP RAISES BHP BILLITON TO 'BUY' ('NEUTRAL') - PRICE TARGET 1400 (1500) PENCE
----------
CITIGROUP RAISES RIO TINTO TO 'BUY' - PRICE TARGET 2800 (2950) PENCE
----------
CITIGROUP CUTS RANDGOLD RESOURCES PRICE TARGET TO 4644 (5228) PENCE - 'NEUTRAL'
----------
CITIGROUP CUTS ANTOFAGASTA PRICE TARGET TO 600 (650) PENCE - 'SELL'
----------
EXANE BNP CUTS SMITHS GROUP PRICE TARGET TO 1090 (1125) PENCE - 'NEUTRAL'
----------
DEUTSCHE BANK CUTS BARCLAYS PRICE TARGET TO 287 (305) PENCE - 'BUY'
----------
EXANE BNP CUTS GKN PRICE TARGET TO 370 (380) PENCE - 'NEUTRAL'
----------
SOCGEN CUTS GKN PRICE TARGET TO 355 (400) PENCE - 'HOLD'
----------
DEUTSCHE BANK CUTS GLAXOSMITHKLINE PRICE TARGET TO 1490 (1540) PENCE - 'HOLD'
----------
EXANE BNP CUTS WEIR GROUP PRICE TARGET TO 1800 (1925) PENCE - 'NEUTRAL'
----------
EXANE BNP RAISES AB FOODS PRICE TARGET TO 3500 (3200) PENCE - 'OUTPERFORM'
----------
BERNSTEIN CUTS MARKS & SPENCER PRICE TARGET TO 535 (595) PENCE - MARKET-PERFORM
----------
BARCLAYS RAISES STANDARD LIFE PRICE TARGET TO 546 (520) PENCE - 'EQUAL WEIGHT'
----------
BARCLAYS RAISES ST JAMES'S PLACE PRICE TARGET TO 1148 (1106) PENCE - OVERWEIGHT
----------
BARCLAYS RAISES RSA INSURANCE PRICE TARGET TO 436 (428) PENCE - 'EQUAL WEIGHT'
----------
BARCLAYS RAISES LEGAL & GENERAL PRICE TARGET TO 289 (285) PENCE - 'OVERWEIGHT'
----------
BARCLAYS RAISES AVIVA PRICE TARGET TO 637 (632) PENCE - 'OVERWEIGHT'
----------
BARCLAYS RAISES ADMIRAL GROUP PRICE TARGET TO 1572 (1523) PENCE - EQUAL WEIGHT
----------
BARCLAYS RAISES PRUDENTIAL PRICE TARGET TO 1889 (1877) PENCE - 'OVERWEIGHT'
----------
BERENBERG RAISES BAE SYSTEMS TO 'BUY' ('HOLD') - TARGET 570 (530) PENCE
----------
FTSE 250
----------
HSBC CUTS SYNTHOMER PRICE TARGET TO 285 (300) PENCE - 'HOLD'
----------
EXANE BNP CUTS VESUVIUS PRICE TARGET TO 470 (480) PENCE - 'OUTPERFORM'
----------
EXANE BNP CUTS SPECTRIS PRICE TARGET TO 2415 (2500) PENCE - 'OUTPERFORM'
----------
EXANE BNP CUTS ROTORK PRICE TARGET TO 200 (220) PENCE - 'UNDERPERFORM'
----------
DEUTSCHE BANK CUTS DRAX GROUP PRICE TARGET TO 270 (370) PENCE - 'HOLD'
----------
GOLDMAN CUTS DRAX GROUP PRICE TARGET TO 285 (411) PENCE - 'NEUTRAL'
----------
BERNSTEIN CUTS DRAX GROUP PRICE TARGET TO 370 (420) PENCE - 'OUTPERFORM'
----------
EXANE BNP CUTS MELROSE PRICE TARGET TO 285 (310) PENCE - 'OUTPERFORM'
----------
EXANE BNP CUTS IMI PRICE TARGET TO 1050 (1080) PENCE - 'UNDERPERFORM'
----------
EXANE BNP RAISES HALMA PRICE TARGET TO 850 (800) PENCE - 'OUTPERFORM'
----------
SOCGEN CUTS IMI PRICE TARGET TO 1400 (1450) PENCE - 'BUY'
----------
PANMURE RAISES BREWIN DOLPHIN HLDGS PRICE TARGET TO 350 (300) PENCE - 'BUY'
----------
SOCGEN INITIATES CRODA WITH 'BUY' - TARGET 3050 PENCE
----------
CITIGROUP CUTS POLYMETAL PRICE TARGET TO 465 (522) PENCE - 'SELL'
----------
JPMORGAN CUTS ASHMORE GROUP PRICE TARGET TO 265 (275) PENCE - 'UNDERWEIGHT'
----------
GOLDMAN CUTS ASHMORE GROUP PRICE TARGET TO 330 (343) PENCE - 'NEUTRAL'
----------
CITIGROUP CUTS PETRA DIAMONDS PRICE TARGET TO 180 (215) PENCE - 'BUY'
----------
JPMORGAN RAISES HAYS PRICE TARGET TO 155 (145) PENCE - 'NEUTRAL'
----------
UBS CUTS LONMIN TO 'SELL' ('NEUTRAL') - TARGET 75 (130) PENCE
----------
CITIGROUP CUTS LONMIN PRICE TARGET TO 113 (144) PENCE - 'NEUTRAL'
----------
CITIGROUP CUTS KAZ MINERALS PRICE TARGET TO 270 (300) PENCE - 'BUY'
----------
CITIGROUP RAISES ACACIA MINING PRICE TARGET TO 312 (283) PENCE - 'NEUTRAL'
----------
BERENBERG RAISES DIGNITY PRICE TARGET TO 2260 (1850) PENCE - 'HOLD'
----------
UBS RAISES MICRO FOCUS PRICE TARGET TO 1460 (1420) PENCE - 'NEUTRAL'
----------
UBS RAISES HALFORDS GROUP PRICE TARGET TO 530 (485) PENCE - 'NEUTRAL'
----------
UBS RAISES DERWENT LONDON PRICE TARGET TO 3750 (3600) PENCE - 'NEUTRAL'
----------
BARCLAYS RAISES PHOENIX GROUP PRICE TARGET TO 794 (790) PENCE - 'UNDERWEIGHT'
----------
BARCLAYS CUTS LANCASHIRE HLDGS PRICE TARGET TO 456 (463) PENCE - 'UNDERWEIGHT'
----------
BARCLAYS CUTS HISCOX PRICE TARGET TO 607 (620) PENCE - 'UNDERWEIGHT'
----------
BARCLAYS RAISES ESURE GROUP PRICE TARGET TO 300 (288) PENCE - 'OVERWEIGHT'
----------
BARCLAYS CUTS AMLIN PRICE TARGET TO 391 (407) PENCE - 'UNDERWEIGHT'
----------
SOCGEN CUTS ASHMORE GROUP PRICE TARGET TO 325 (350) PENCE - 'BUY'
----------
BERENBERG CUTS BALFOUR BEATTY PRICE TARGET TO 250 (260) PENCE - 'BUY'
----------
MAIN MARKET AND AIM
----------
CITIGROUP CUTS SOUTH32 PRICE TARGET TO 110 (140) PENCE - 'BUY'
----------
CITIGROUP RAISES PETROPAVLOVSK PRICE TARGET TO 6 (5) PENCE - 'SELL'
----------
CITIGROUP CUTS POLYUS GOLD PRICE TARGET TO 185 (194) PENCE - 'NEUTRAL'
----------
CITIGROUP RAISES HOCHSCHILD MINING PRICE TARGET TO 75 (65) PENCE - 'SELL'
----------
CITIGROUP CUTS GEM DIAMONDS PRICE TARGET TO 155 (161) PENCE - 'NEUTRAL'
----------
CITIGROUP RAISES FERREXPO PRICE TARGET TO 38 (31) PENCE - 'SELL'
----------
BARCLAYS RAISES PARTNERSHIP PRICE TARGET TO 117 (111) PENCE - 'UNDERWEIGHT'
----------
BERENBERG CUTS PENDRAGON PRICE TARGET TO 44 (45) PENCE - 'BUY'
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.